Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
6.00
+0.07 (1.18%)
At close: Sep 4, 2026, 4:00 PM EDT
6.01
+0.01 (0.15%)
After-hours: Sep 4, 2026, 7:30 PM EDT

Abeona Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
25.525.82-3.51.413
Revenue Growth
6280.00%--147.53%-52.87%-70.00%
Cost of Revenue
35.730.2434.3632.729.4238.73
Gross Profit
-10.18-24.42-34.36-29.2-28-35.73
Selling, General & Admin
73.4365.0329.851917.2621.64
Operating Expenses
73.4365.0329.851917.2621.64
Operating Income
-83.62-89.45-64.21-48.2-45.26-57.37
Interest Expense
-3.31-3.74-4.21-0.42-0.74-3.66
Interest & Investment Income
5.935.564.252.120.430.04
Other Non Operating Income (Expenses)
2.76.550.44-8.7111.660.02
EBT Excluding Unusual Items
-78.3-81.08-63.74-55.21-33.9-60.97
Impairment of Goodwill
------32.47
Gain (Loss) on Sale of Assets
-152.370-0.05-0.14-
Asset Writedown
---1.07-5.66-
Other Unusual Items
-----8.5
Pretax Income
-78.371.28-63.73-54.19-39.7-84.94
Income Tax Expense
-15.410.1----
Net Income
-62.8971.18-63.73-54.19-39.7-84.94
Preferred Dividends & Other Adjustments
----3.78-
Net Income to Common
-62.8971.18-63.73-54.19-43.48-84.94
Net Income Growth
------
Shares Outstanding (Basic)
5653412184
Shares Outstanding (Diluted)
5666412184
Shares Change
-1.73%61.12%91.99%171.96%99.65%6.24%
EPS (Basic)
-1.131.34-1.55-2.53-5.53-21.57
EPS (Diluted)
-1.181.01-1.55-2.53-5.53-21.57
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-81.53-84.3-58.46-37.34-43.61-69.82
Free Cash Flow Per Share
-1.46-1.27-1.42-1.75-5.55-17.73
Gross Margin
-39.90%-----
Operating Margin
-327.64%-1536.91%--1377.14%-3200.64%-1912.33%
Profit Margin
-246.42%1223.08%--1548.23%-3074.82%-2831.20%
Free Cash Flow Margin
-319.46%-1448.47%--1066.86%-3084.37%-2327.20%
EBITDA
-80.79-86.9-62.21-45.91-42.16-54.12
D&A For EBITDA
2.832.5522.293.093.25
EBIT
-83.62-89.45-64.21-48.2-45.26-57.37
Effective Tax Rate
-0.14%----
Revenue as Reported
25.525.82----
SEC Filings: 10-K · 10-Q